Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Cardiac Sciences
    • Switching to oral...

    Switching to oral antibiotics halves hospital stay in endocarditis : ESC Update

    Written by Dr. Kamal Kant Kohli Kohli Published On 2018-08-29T19:28:51+05:30  |  Updated On 29 Aug 2018 7:28 PM IST
    Switching to oral antibiotics halves hospital stay in endocarditis : ESC Update

    In late-breaking results of the POET trial presented in ESC Congress 2018, it has been found that Oral treatment can halve hospital stay in endocarditis. Patients with infective endocarditis on the left side of the heart are typically treated with intravenous antibiotic agents for up to 6 weeks as per guidelines. Switching to oral antibiotics once an endocarditis patient is stable appears safe and could allow them to head home from the hospital sooner, the randomized Partial Oral Treatment of Endocarditis (POET) trial showed. The study has been published in the New England Journal of Medicine.


    Professor Henning Bundgaard at Copenhagen University Hospital, Denmark, Dr Kasper Iversen and colleagues carried out a study to investigate whether a shift from intravenous to oral antibiotics in infective endocarditis would result in efficacy and safety similar to those with continued intravenous treatment once the patient is in stable condition.


    Professor Henning Bundgaard said: “It is a huge challenge for patients to stay in the hospital for up to six weeks receiving intravenous treatment, which is associated with an increased risk of complications. Reducing the length of hospital stay has improved outcomes in other diseases and oral antibiotics could be a safe way to achieve this.”


    Endocarditis is an infection of the inner lining of the heart and one or more heart valves and is usually caused by bacteria entering the blood and travelling to the heart. Intensive care is sometimes needed and the mortality is as high as around 15–30% of patients. Up to half of the patients require surgery to remove infected tissue and repair or replace infected heart valves. After the initial phase and after surgery most patients are clinically stable and the main reason for staying in the hospital is to complete up to six weeks of intravenous antibiotic treatment as recommended by guidelines.


    In the POET trial after at least ten days of intravenous antibiotics, 400 clinically stable patients with endocarditis were randomly allocated to continued intravenous antibiotics or to oral antibiotics. Patients in the oral antibiotics group were offered treatment as outpatients. After randomisation, intravenous or oral antibiotics were taken for a median of 18 days. They were followed-up for six months after antibiotic treatment had finished for the combined endpoint of all-cause death, unplanned cardiac surgery, embolic events, and reinfection.


    The group getting oral tablets after at least 10 days IV antibiotics had a 9.0% rate of all-cause mortality, unplanned cardiac surgery, embolic events, or relapse of bacteremia with the primary pathogen by 6 months after completion of treatment which was non inferior to the 12.1% in the IV-only antibiotic group.


    The primary endpoint occurred in 10.5% of patients without any significant difference between the two groups thereby meaning that the non-inferiority criterion was met and a change to oral treatment was as efficient and safe as the conventional continued intravenous treatment for the whole period.


    Professor Bundgaard said: “Shifting to oral antibiotic treatment in stabilised patients with endocarditis was as effective and safe as continued intravenous antibiotic treatment and was given during half the antibiotic treatment period. These novel findings may have a significant impact on future clinical practice for the management of patients who are stable.”

    EndocarditisendocardiumESC Updateheart infectionhospital stayInfectiveintravenousNEJMnewNew England Journal of Medicineoral treatmentPOET trialreduceShifting toshortenvalve
    Source : New England Journal of Medicine

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Dr. Kamal Kant Kohli Kohli
    Dr. Kamal Kant Kohli Kohli
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok